These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38933431)

  • 21. The Global Programme to Eliminate Lymphatic Filariasis: History and achievements with special reference to annual single-dose treatment with diethylcarbamazine in Samoa and Fiji.
    Kimura E
    Trop Med Health; 2011 Mar; 39(1):17-30. PubMed ID: 22028608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence for stopping mass drug administration for lymphatic filariasis in some, but not all local government areas of Plateau and Nasarawa States, Nigeria.
    King JD; Eigege A; Umaru J; Jip N; Miri E; Jiya J; Alphonsus KM; Sambo Y; Graves P; Richards F
    Am J Trop Med Hyg; 2012 Aug; 87(2):272-80. PubMed ID: 22855758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes.
    Bockarie MJ; Alexander ND; Hyun P; Dimber Z; Bockarie F; Ibam E; Alpers MP; Kazura JW
    Lancet; 1998 Jan; 351(9097):162-8. PubMed ID: 9449870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two-year follow-up of the microfilaraemia of asymptomatic brugian filariasis, after treatment with two, annual, single doses of ivermectin, diethylcarbamazine and albendazole, in various combinations.
    Shenoy RK; John A; Babu BS; Suma TK; Kumaraswami V
    Ann Trop Med Parasitol; 2000 Sep; 94(6):607-14. PubMed ID: 11064762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Filariasis in Africa--treatment challenges and prospects.
    Hoerauf A; Pfarr K; Mand S; Debrah AY; Specht S
    Clin Microbiol Infect; 2011 Jul; 17(7):977-85. PubMed ID: 21722251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of six rounds of single dose mass treatment with diethylcarbamazine or ivermectin on Wuchereria bancrofti infection and its implications for lymphatic filariasis elimination.
    Ramaiah KD; Vanamail P; Pani SP; Yuvaraj J; Das PK
    Trop Med Int Health; 2002 Sep; 7(9):767-74. PubMed ID: 12225508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti.
    de Kraker ME; Stolk WA; van Oortmarssen GJ; Habbema JD
    Trop Med Int Health; 2006 May; 11(5):718-28. PubMed ID: 16640625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrated transmission assessment surveys (iTAS) of lymphatic filariasis and onchocerciasis in Cross River, Taraba and Yobe States, Nigeria.
    Anagbogu IN; Saka YA; Surakat OA; Okoronkwo C; Davies E; Oyale P; Ekpo UF; Amazigo UV; Barbre K; Igbe M; Nyior A; Jacob SM; Gideon Nteun U; Abubakar Umar Z
    Parasit Vectors; 2022 Jun; 15(1):201. PubMed ID: 35698164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymphatic filariasis transmission in Rufiji District, southeastern Tanzania: infection status of the human population and mosquito vectors after twelve rounds of mass drug administration.
    Jones C; Ngasala B; Derua YA; Tarimo D; Reimer L; Bockarie M; Malecela MN
    Parasit Vectors; 2018 Nov; 11(1):588. PubMed ID: 30424781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial.
    Tavul L; Laman M; Howard C; Kotty B; Samuel A; Bjerum C; O'Brian K; Kumai S; Amuga M; Lorry L; Kerry Z; Kualawi M; Karl S; Makita L; John LN; Bieb S; Wangi J; Weil GJ; Goss CW; Tisch DJ; Pomat W; King CL; Robinson LJ
    PLoS Negl Trop Dis; 2022 Feb; 16(2):e0010096. PubMed ID: 35139070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imported bancroftian filariasis: diethylcarbamazine response and benzimidazole susceptibility of Wuchereria bancrofti in dynamic cross-border migrant population targeted by the National Program to Eliminate Lymphatic Filariasis in South Thailand.
    Bhumiratana A; Pechgit P; Koyadun S; Siriaut C; Yongyuth P
    Acta Trop; 2010 Feb; 113(2):121-8. PubMed ID: 19835831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lymphatic filariasis and onchocerciasis.
    Taylor MJ; Hoerauf A; Bockarie M
    Lancet; 2010 Oct; 376(9747):1175-85. PubMed ID: 20739055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of six rounds of single-dose mass administration of diethylcarbamazine or ivermectin on the transmission of Wuchereria bancrofti by Culex quinquefasciatus and its implications for lymphatic filariasis elimination programmes.
    Ramaiah KD; Das PK; Vanamail P; Pani SP
    Trop Med Int Health; 2003 Dec; 8(12):1082-92. PubMed ID: 14641843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India.
    Kshirsagar NA; Gogtay NJ; Garg BS; Deshmukh PR; Rajgor DD; Kadam VS; Thakur PA; Gupta A; Ingole NS; Lazdins-Helds JK
    Parasitol Res; 2017 Oct; 116(10):2683-2694. PubMed ID: 28785847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters.
    Wamae CN; Njenga SM; Ngugi BM; Mbui J; Njaanake HK
    Acta Trop; 2011 Sep; 120 Suppl 1():S33-8. PubMed ID: 20933491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial.
    Laman M; Tavul L; Karl S; Kotty B; Kerry Z; Kumai S; Samuel A; Lorry L; Timinao L; Howard SC; Makita L; John L; Bieb S; Wangi J; Albert JM; Payne M; Weil GJ; Tisch DJ; Bjerum CM; Robinson LJ; King CL
    Lancet Infect Dis; 2022 Aug; 22(8):1200-1209. PubMed ID: 35533701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of two rounds of mass treatment with diethylcarbamazine plus albendazole on Wuchereria bancrofti infection and the sensitivity of immunochromatographic test in Malindi, Kenya.
    Njenga SM; Wamae CN; Njomo DW; Mwandawiro CS; Molyneux DH
    Trans R Soc Trop Med Hyg; 2008 Oct; 102(10):1017-24. PubMed ID: 18550135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.
    Jambulingam P; Kuttiatt VS; Krishnamoorthy K; Subramanian S; Srividya A; Raju HKK; Rahi M; Somani RK; Suryaprakash MK; Dwivedi GP; Weil GJ
    PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009069. PubMed ID: 33591979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lymphatic filariasis control in Tanzania: effect of six rounds of mass drug administration with ivermectin and albendazole on infection and transmission.
    Simonsen PE; Derua YA; Kisinza WN; Magesa SM; Malecela MN; Pedersen EM
    BMC Infect Dis; 2013 Jul; 13():335. PubMed ID: 23870103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How Does the Proportion of Never Treatment Influence the Success of Mass Drug Administration Programs for the Elimination of Lymphatic Filariasis?
    Kura K; Stolk WA; Basáñez MG; Collyer BS; de Vlas SJ; Diggle PJ; Gass K; Graham M; Hollingsworth TD; King JD; Krentel A; Anderson RM; Coffeng LE
    Clin Infect Dis; 2024 Apr; 78(Supplement_2):S93-S100. PubMed ID: 38662701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.